
SeQure DX is setting the standard for precision analytics in gene editing, delivering best-in-class off-target risk assessment services to advance safer, more effective cell and gene therapies.
We provide a comprehensive suite of trusted assays—such as ONE-seq, GUIDE-seq, DEUX-seq, Amplicon-seq, Guide Profiler, Guide Select, and SAFER Detection—that enable developers to detect, nominate, and confirm gene editing outcomes with high sensitivity and regulatory alignment.
In January 2025, SeQure DX was acquired by MaxCyte, Inc., a leading cell engineering company, to form the core of MaxCyte’s Cell & Gene Therapy (CGT) Services business. Together, we provide an integrated solution that combines world-class cell engineering and comprehensive gene editing risk assessment services, helping therapeutic developers mitigate risk in their programs, accelerate timelines, and enable regulatory confidence from discovery through clinical stage and beyond.
SeQure DX operates in the Biotechnology Research industry and is headquartered in United States.
SeQure DX has approximately 51-200 employees employees.
SeQure DX is based in Waltham, MA, United States.
Yes. SeQure DX is a publicly traded company.
You can reach SeQure DX’s investor relations department through the contact section on their official website or directly via the investor relations email listed in their latest SEC filings.
Up to 90% verified emails and mobile numbers, backed by weekly job-change alerts.
An email pattern tells you the format. It does not tell you who works there now or whether an address still delivers. Scalelist returns verified contacts, checked at the point you build the list.
Our team will be in touch soon. If you have any questions, please email us at info@scalelist.com
Just a few more details..
Our team will be in touch soon. If you have any questions, please email us at arnaud@scalelist.com